Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Kinect-2 Puts '854 Back Into Play For Neurocrine

Tuesday is going to be a good day for Neurocrine Biosciences (NASDAQ:NBIX) and its shareholders. Strong data from the Phase IIb Kinect-2 study of NBI-98854 ('854) in tardive dyskinesia surprised the Street in a big way, and the shares are poised to jump as a potentially valuable drug suddenly looks much more viable than just a few months ago.

When it comes to the stock market and clinical trial data coming out of biotechs, the reactions often remind me of a cat chasing a laser pointer. Keep that in mind when contemplating the ultimate odds of approval and the challenges in designing a Phase III study that will not only cast the drug in the best light, but...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details